Please assess the completion status of the following clinical trial:

Trial Title: Reducing Suicidal Ideation Through Insomnia Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons 18-65 years of age~* Persons with confirmed DSM-IV diagnosis of MDE by SCID~* Persons with Research Diagnostic Criteria diagnosis of insomnia~* Persons free of all psychotropic medications for one week before baseline assessment, except that prior FLX treatment will require 4 weeks of abstinence, and MAOIs will require 2 weeks of abstinence.~* Persons with Scale for Suicide Ideation (SSI) scores \>2~* Persons with Hamilton Rating Scale for Depression (HRSD24) score \>20~* Persons with Mini Mental State Exam (MMSE) score \>24~* Persons with Insomnia Severity Index (ISI) score \> 7~* Persons with habitual sleep latency \> or = 30 minutes or wake time in the middle of the night of \> or = 30 minutes, and sleep efficiency \< 85%~Exclusion Criteria:~* Non-English speaking, reading, writing persons~* Persons who pose imminent danger to self or others~* Persons with severe suicidal ideation (C-SSRS Suicidal Ideation Score \>3)~* Persons with clinical diagnosis of dementia~* Persons with active or past diagnosis of alcohol or substance abuse, bipolar disorder, schizophrenia per the SCID~* Persons who screen positive for moderate-severe sleep apnea (AHI \>10) or a prior sleep laboratory-confirmed diagnosis of a primary sleep disorder, such as sleep apnea or periodic limb movement disorder.~* Persons with BMI \> 50~* Persons with a self-reported history of napping \> 2 times per week (as these are associated with sleep apnea and periodic limb movement disorder in depressed insomniacs)~* Persons who might be harmed by exposure to hypnotics, including pregnant women and patients with respiratory conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Zolpidem-CR (Type: ACTIVE_COMPARATOR): Zolpidem 6.25 or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).